Jaguar Health Stock Forecast, Price & News

Wall Street analysts have given Jaguar Health a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Jaguar Health wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Jaguar Health saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 4,970,000 shares, an increase of 26.1% from the March 15th total of 3,940,000 shares. Based on an average trading volume of 23,960,000 shares, the days-to-cover ratio is currently 0.2 days.
View Jaguar Health's Short Interest.

Jaguar Health is scheduled to release its next quarterly earnings announcement on Friday, May 21st 2021.
View our earnings forecast for Jaguar Health.

Jaguar Health, Inc. (NASDAQ:JAGX) released its quarterly earnings results on Sunday, November, 15th. The biotechnology company reported ($0.21) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.11) by $0.10. The biotechnology company earned $2.77 million during the quarter. Jaguar Health had a negative net margin of 372.81% and a negative trailing twelve-month return on equity of 659.73%.
View Jaguar Health's earnings history.

Jaguar Health's stock was trading at $0.45 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, JAGX stock has increased by 188.9% and is now trading at $1.30.
View which stocks have been most impacted by COVID-19.

Some companies that are related to Jaguar Health include Chinook Therapeutics (KDNY), Kadmon (KDMN), Emisphere Technologies (EMIS), Calliditas Therapeutics AB (publ) (CALT), Intercept Pharmaceuticals (ICPT), Gossamer Bio (GOSS), Clovis Oncology (CLVS), Albireo Pharma (ALBO), Evelo Biosciences (EVLO), Rigel Pharmaceuticals (RIGL), IDEAYA Biosciences (IDYA), AnaptysBio (ANAB), KalVista Pharmaceuticals (KALV), OrganiGram (OGI) and Eagle Pharmaceuticals (EGRX).
View all of JAGX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Jaguar Health investors own include Biocept (BIOC), Sorrento Therapeutics (SRNE), Trevena (TRVN), Vaxart (VXRT), Purple Biotech (KTOV), Onconova Therapeutics (ONTX), Tonix Pharmaceuticals (TNXP), Biopharmx (BPMX), Cara Therapeutics (CARA) and Conatus Pharmaceuticals (CNAT).

(JAGX) raised $22 million in an initial public offering on Wednesday, May 13th 2015. The company issued 3,200,000 shares at a price of $7.00 per share. Aegis Capital Corp acted as the underwriter for the IPO and CRT Capital and Feltl and Company were co-managers.

Jaguar Health trades on the NASDAQ under the ticker symbol "JAGX."

Shares of JAGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of JAGX stock can currently be purchased for approximately $1.30.

Jaguar Health has a market capitalization of $169.04 million and generates $5.78 million in revenue each year. The biotechnology company earns $-38,540,000.00 in net income (profit) each year or ($6.89) on an earnings per share basis.

Jaguar Health employs 29 workers across the globe.

The official website for Jaguar Health is www.jaguaranimalhealth.com.

Jaguar Health is headquartered at 201 MISSION STREET SUITE 2375, SAN FRANCISCO CA, 94105.

Jaguar Health's mailing address is 201 MISSION STREET SUITE 2375, SAN FRANCISCO CA, 94105. The biotechnology company can be reached via phone at (415) 371-8300.